RxDoctor Payments Data

Carene Weinand

Family · Douglas, WYNPI 1407514573

Payments from drug & device makers

$740in general payments, 2019–2025

Across 41 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$249
  • Lilly USA, LLC$163
  • Novo Nordisk$119
  • Novartis$102
  • Sanofi-aventis U.S. LLC$50
  • Amgen$29
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$249
Lilly USA, LLC11$163
Novo Nordisk5$119
Novartis6$102
Sanofi-aventis U.S. LLC3$50
Amgen2$29
Pfizer1$14
Merck1$14

How this compares

$740 in reported general payments places this provider in the 75th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$4,251
Medicare patients
14
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$75,959
OzempicSemaglutide39$45,080
FarxigaDapagliflozin Propanediol22$25,376
XareltoRivaroxaban13$21,396
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$20,883
EliquisApixaban23$16,681
MyrbetriqMirabegron12$5,211
Incruse ElliptaUmeclidinium Bromide12$4,257
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,786
Estradiol124$2,024
Ezetimibe46$1,582
ProgesteroneProgesterone, Micronized51$1,242
Omeprazole72$1,215
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,099
Gabapentin93$1,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$163$75,95972 claims
AstraZenecaFarxiga, Breztri Aerosphere$249$46,26053 claims
Novo NordiskOzempic$119$45,08039 claims
PfizerEliquis$14$16,68123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 284 family providers in Wyoming.

Other family in Douglas

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →